Background -In normal subjects intravenous adenosine infusion has been shown to stimulate ventilation with a consequent fall in arterial partial pressure of carbon dioxide (Paco2), probably by an action on the carotid bodies. 
Abstract
Background -In normal subjects intravenous adenosine infusion has been shown to stimulate ventilation with a consequent fall in arterial partial pressure of carbon dioxide (Paco2), probably by an action on the carotid bodies. The objective of this study was to determine whether the increase in Paco2 seen when patients with ventilatory failure secondary to chronic obstructive pulmonary disease ( Adenosine is known to stimulate breathing in normal humans. [1] [2] [3] This is likely to be mediated by an action on the carotid bodies45 and may relate to an effect on hypoxic chemosensitivity.56 However, the effect of this nucleoside on breathing in patients with chronic obstructive pulmonary disease (COPD) has not been reported. A common problem in the management of such patients (particularly during acute exacerbations) is an increase in the arterial carbon dioxide tension (Paco,) capillary tube from the anterior nares. The infusion was continued whilst breathing this high inspired oxygen concentration for 20 minutes. If unpleasant side effects such as headache, flushing, or dyspnoea were experienced the infusion rate was reduced to a level felt to be tolerable by the subject. After the 20 minutes of oxygen administration, the oxygen and infusion were discontinued and the patient rested for at least one hour. The procedure was then repeated with the second infusion. FEV, and FVC were measured before and at the end of each infusion with a turbine spirometer (Micro Spirometer, Micro Medicals, Rochester, UK).
DATA ANALYSIS
Values reported are mean (SE) with 95% confidence intervals (95% CI) for main results. Observations were analysed at three time points during the experiment -that is, at rest, at the end of the infusion alone, and at the end of the infusion + oxygen for each treatment. Analysis of variance with repeated measuresusing the three time points as the repeated measures factors and saline and adenosine as the treatment factors -was used to investigate changes in Ptcco2 with experimental time point and drug given. The Student's paired t test was used to investigate differences between the experimental observations and their respective baseline values. The paired t test was also used to determine differences between mean values of observations between the two arms of the study. A p value of <0.05 was regarded as significant.
Results
In three subjects the maximum infusion rate of adenosine was reduced because of side effects, primarily dyspnoea. In these subjects the final infusion rates were 70, 60, and 20,g/kg/min. The spirometric values before and after the saline infusion showed no statistically sig- However, there was a small but statistically significant fall in FVC following adenosine infusion from 1.67 (95% CI 1.03 to 2.31) I before to 1.57 (95% CI 0.93 to 2.21) 1 after the infusion (mean difference -0.10 (95% CI -0.17 to -0.03) 1; p<0.02). The heart rate at rest, at the end of drug infusion, and at the end of infusion with oxygen was 85 (9) , 87 (8) , and 86 (7) beats/min, respectively, for saline and 86 (9) , 85 (9) , and 87 (7) beats/min, respectively, for adenosine. The differences between the two infusions at each point were not statistically significant.
Analysis of variance showed a significant effect of experimental time point on Sao, (p<0.000 1). There was, however, no significant effect of the drugs on this relationship with these responses on the two drugs, are shown in table 1. During the saline arm of the study there was, overall, a significant rise in Ptcco2 which was greater than that seen with adenosine. In contrast, Ptcco2 fell significantly during the lone adenosine infusion, this fall being greater than the change seen with saline.
Although the rise in Ptcco2 seen with the addition of oxygen to the inspirate during the saline infusion was twice as great as when oxygen was added during the adenosine infusion, the mean difference between treatments of 0.33 (95% CI -0.04 to 0.70) kPa just failed to achieve statistical significance (p = 0.06). The mean changes from baseline to end of infusion and from baseline to infusion + oxygen, together with the differences between Discussion We were interested to determine whether intravenous infusion of adenosine would ameliorate the increase seen in Pco2 when patients with ventilatory failure secondary to COPD are given a high concentration ofoxygen to breathe. Our findings suggest, firstly, that intravenous infusion of adenosine whilst breathing room air is accompanied by a fall in Pco2 and, secondly, that when a hyperoxic inspirate is administered to patients with ventilatory failure concomitant intravenous adenosine infusion prevents a rise in Pco2 above baseline levels in spite of a small but significant reduction in dynamic lung volumes. Significant effects of adenosine on Sao2 were not encountered in our patients.
With infusion of adenosine both FEV1 and FVC fell slightly (FVC significantly so), suggesting that intravenous adenosine may have a small effect on airway calibre in patients with COPD. This is in keeping with the observation that intravenous bolus doses of adenosine can provoke bronchospasm in patients with COPD.9 Interestingly, inhaled adenosine causes bronchoconstriction in asthmatic patients'" but intravenous infusion of up to 50 Ztg/kg/min does not alter their airway conductance."1 Thus, the effect we have found may reflect a susceptibility of the bronchial smooth muscle in patients with COPD to the bronchoconstrictor effects of adenosine. Whilst adenosine infusion was not accompanied by detrimental changes in Sao2 in our subjects, the finding of reduced spirometric values suggests that adenosine infusion should be used with caution in patients with very severe airflow limitation.
Another important effect of adenosine infusion which might affect oxygen delivery is an increased heart rate which has been described in normal subjects.231213 We, however, did not detect any significant difference in heart rate between saline and adenosine infusions in our patients with COPD, which may reflect the relatively low infusion rate used in the present study. We monitored changes in Pco2 transcutaneously. Transcutaneous monitoring has whether a similar beneficial effect on Pco2 would be seen if adenosine were to be used in conjunction with oxygen treatment during acute on chronic exacerbations of COPD when the drive to breathe may already be high.
In conclusion, we have found that a continuous intravenous infusion of adenosine results in a fall in Ptcco2 and counteracts the rise in Ptcco2 seen in patients with ventilatory failure secondary to COPD when breathing an oxygen rich inspirate. A small reduction in dynamic lung volumes is also seen during adenosine infision in these patients. 
